Numa, K.; Kakimoto, K.; Tanaka, Y.; Mizuta, N.; Kinoshita, N.; Nakazawa, K.; Koshiba, R.; Hirata, Y.; Ota, K.; Miyazaki, T.;
et al. Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis. J. Clin. Med. 2023, 12, 6699.
https://doi.org/10.3390/jcm12206699
AMA Style
Numa K, Kakimoto K, Tanaka Y, Mizuta N, Kinoshita N, Nakazawa K, Koshiba R, Hirata Y, Ota K, Miyazaki T,
et al. Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis. Journal of Clinical Medicine. 2023; 12(20):6699.
https://doi.org/10.3390/jcm12206699
Chicago/Turabian Style
Numa, Keijiro, Kazuki Kakimoto, Yasuyoshi Tanaka, Noboru Mizuta, Naohiko Kinoshita, Kei Nakazawa, Ryoji Koshiba, Yuki Hirata, Kazuhiro Ota, Takako Miyazaki,
and et al. 2023. "Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis" Journal of Clinical Medicine 12, no. 20: 6699.
https://doi.org/10.3390/jcm12206699
APA Style
Numa, K., Kakimoto, K., Tanaka, Y., Mizuta, N., Kinoshita, N., Nakazawa, K., Koshiba, R., Hirata, Y., Ota, K., Miyazaki, T., Nakamura, S., Higuchi, K., & Nishikawa, H.
(2023). Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis. Journal of Clinical Medicine, 12(20), 6699.
https://doi.org/10.3390/jcm12206699
